GSK Stock - GSK plc
Unlock GoAI Insights for GSK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $31.38B | $30.33B | $29.32B | $24.70B | $24.35B |
| Gross Profit | $22.33B | $21.76B | $19.77B | $16.53B | $16.43B |
| Gross Margin | 71.2% | 71.8% | 67.4% | 66.9% | 67.4% |
| Operating Income | $4.02B | $6.75B | $6.43B | $4.36B | $5.98B |
| Net Income | $2.58B | $4.93B | $14.96B | $4.38B | $5.75B |
| Net Margin | 8.2% | 16.2% | 51.0% | 17.8% | 23.6% |
| EPS | $1.26 | $2.44 | $2.44 | $2.74 | $2.88 |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
Visit WebsiteEarnings History & Surprises
GSKEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | $0.65 | — | — | — |
Q4 2025 | Oct 28, 2025 | — | $0.98 | — | — |
Q3 2025 | Jul 30, 2025 | — | $0.96 | — | — |
Q2 2025 | Apr 30, 2025 | $1.08 | $1.13 | +4.6% | ✓ BEAT |
Q1 2025 | Feb 5, 2025 | $0.44 | $0.59 | +34.1% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $1.16 | $1.27 | +9.5% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $1.00 | $1.09 | +9.0% | ✓ BEAT |
Q1 2024 | Jan 31, 2024 | $0.76 | $0.72 | -5.3% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $1.09 | $1.26 | +15.6% | ✓ BEAT |
Q3 2023 | Jul 26, 2023 | $0.87 | $0.97 | +11.5% | ✓ BEAT |
Q2 2023 | Apr 26, 2023 | $0.82 | $0.90 | +9.8% | ✓ BEAT |
Q1 2023 | Feb 1, 2023 | $0.59 | $0.64 | +8.5% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $0.96 | $1.10 | +14.6% | ✓ BEAT |
Q3 2022 | Jul 27, 2022 | $0.76 | $0.87 | +14.5% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $0.96 | $1.10 | +14.6% | ✓ BEAT |
Q1 2022 | Feb 9, 2022 | $0.81 | $0.86 | +6.2% | ✓ BEAT |
Q4 2021 | Oct 27, 2021 | $1.00 | $1.26 | +26.0% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $0.64 | $0.98 | +53.1% | ✓ BEAT |
Q2 2021 | Apr 28, 2021 | $0.76 | $0.79 | +3.9% | ✓ BEAT |
Latest News
Frequently Asked Questions about GSK
What is GSK's current stock price?
What is the analyst price target for GSK?
What sector is GSK plc in?
What is GSK's market cap?
Does GSK pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to GSK for comparison